Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
28,754,017
-
Share change
-
+1,479,007
-
Total reported value
-
$391,052,386
-
Put/Call ratio
-
114%
-
Price per share
-
$13.60
-
Number of holders
-
76
-
Value change
-
+$16,928,575
-
Number of buys
-
42
-
Number of sells
-
29
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2016
As of 30 Jun 2016 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 28,754,017 shares of stock of the company.
Largest 10 holders included Essex Woodlands Health Ventures, Inc., JPMORGAN CHASE & CO, FRANKLIN RESOURCES INC, NQ HCIF GP, Ltd., WELLINGTON MANAGEMENT GROUP LLP, Bank of New York Mellon Corp, Arrowpoint Asset Management, LLC, BlackRock Fund Advisors, Polar Capital LLP, and VANGUARD GROUP INC.
This table shows 76 institutional shareholders of the security as of 30 Jun 2016.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.